TD Cowen analyst Phil Nadeau reiterated a Buy rating on Editas Medicine (NASDAQ: EDIT)The analyst commented, "EDIT ended Q4 with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE